Deerfield Beach, FL -- (SBWIRE) -- 07/25/2016 -- EGFR is the primary receptor recognized in a group of receptors and is a cell surface protein that binds to epidermal growth factor. EGFR is a cell membrane growth factor receptor characterized by tyrosine kinase receptor which plays very important role in the control of key cellular transduction pathways in both normal and cancerous cells. EGFR is the first molecular target against which monoclonal antibodies (mAb) have been developed in cancer therapy.

On the basis of types, the global epidermal growth factor receptor (EGFR) antibodies market is segmented into cetuximab, panitumumab, and nimotuzumab. Cetuximab and panitumumab are the most favored EGFR antibodies which are utilized for treatment of cancer. Nimotuzumab is a humanized monoclonal antibody that recognizes the EGFR antibody. These antibodies are used in the treatment of colorectal tumor as single chairmen and in mix with routine chemotherapy.

Read More@ http://www.syndicatemarketresearch.com/market-analysis/epidermal-growth-factor-receptor-egfr-antibodies-market-global.html

The report covers forecast and analysis for the epidermal growth factor receptor (EGFR) antibodies market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million). The report also offers detailed competitive landscape of the global epidermal growth factor receptor (EGFR) antibodies market. It includes company market share analysis, product portfolio of the major industry participants. The report provides detailed segmentation of the epidermal growth factor receptor (EGFR) antibodies market based on type segment. Cetuximab, panitumumab, and nimotuzumab are different type of EGFR antibodies.

Increasing rate of cancer around the world, and advancement in the treatments are few drivers for EGFR antibody market. Prevalence of cancer is high in North America specifically in U.S. Cancer cases globally are escalating at an alarming rate. Cancer represents a key challenge to development, undermining economic and social advances all over the world. Breast cancer is most common diagnosed cancer and second leading cause of death amongst women in the U.S. According to World Cancer Report, produced by the WHO's specialized cancer agency, predicted that new cancer cases would rise from 14 million annually in 2012 to 22 million within two decades.

Get Free Sample Report@ http://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=67199

Geographically, epidermal growth factor receptor (EGFR) antibodies market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. EGFR antibody market was dominated by North America followed by Europe. Key players in this market are Biocon ltd, Bristol-Myers Squibb, Vaccinex, NovelMed Therapeutics, Janssen Biotech (J&J), Merck, Angiochem , Bio-Synthesis, Antibody Systems

Inquiry Before Buying@ http://www.syndicatemarketresearch.com/market-analysis/epidermal-growth-factor-receptor-egfr-antibodies-market-global.html#inquiry-for-buying

Epidermal Growth Factor Receptor (EGFR) Antibodies Market: Type Segment Analysis
-Cetuximab
-Panitumumab
-Nimotuzumab

Epidermal Growth Factor Receptor (EGFR) Antibodies Market: Regional Segment Analysis
-North America
-U.S.
-Europe
-UK
-France
-Germany
-Asia Pacific
-China
-Japan
-India
-Latin America
-Brazil
-Middle East & Africa

Contact US:
Joel John
3422 SW 15 Street,Suite #8138
Deerfield Beach,Florida 33442
United States
Toll Free: 855-465-4651 (USA-CANADA)
Tel: 386-310-3803
Email: sales@syndicatemarketresearch.com
Website: http://www.syndicatemarketresearch.com